Stock Track | Mabwell Bio Soars 6.44% Intraday on Strong Q1 Revenue Growth and Stock Connect Inclusion

Stock Track
04/30

Mabwell Bio's stock price surged 6.44% during intraday trading on Thursday, marking a significant rebound in its share price.

The sharp rise appears to be driven by the company's recently reported first-quarter financial results, which showed revenue skyrocketing 184.89% year-over-year to RMB 128 million, while net losses narrowed by 17.07%. Additionally, the stock's recent inclusion in the Stock Connect program following its H-share listing has enhanced liquidity by enabling direct participation from mainland investors.

Market attention is also focused on the company's pipeline of ADC and TCE-based oncology therapies, with Phase III interim analyses for its lead candidate expected this year, contributing to positive investor sentiment.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10